Kodiak Sciences Q4 net loss $70.4M ($1.35/sh); cash $478.9M; tarcocimab data Q3 2023

Kodiak Sciences Inc.

Cash, equivalents and marketable securities totaled $478.9M at Dec 31, 2022.
Q4 2022 net loss $70.4M ($1.35/sh) vs Q4 2021 net loss $93.2M ($1.79/sh).
R&D expenses $56.0M in Q4 2022, down from $75.6M; G&A $18.1M vs $17.5M.
Topline data from 4 Phase 3 tarcocimab studies (DME, NPDR, wAMD) expected Q3 2023.
KSI-501 Phase 1 in DME screening patients; commercial cGMP manufacturing started at Ursus.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kodiak Sciences Inc. reported financial results for the fourth quarter ended December 31, 2022.

Period: the fourth quarter ended December 31, 2022
Result: reported results

Exact text from the filing

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Kodiak Sciences Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-010303

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.